Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hemophilia Treatment Market

Hemophilia Treatment Market Share

Report ID: GMI2772
Published Date: Feb 2022
Report Format: PDF

Download Free Sample

Hemophilia Treatment Market Share

Some of the major players operating in the hemophilia treatment industry are:

Bayer Healthcare
Biogen
Biotest AG
CSL Behring
Ferring B.V
Genentech
Kedrion
Novo Nordisk
Octapharma

These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for hemophilia treatment exceeded $11.1 billion in 2021 and is predicted to record around 5% CAGR over 2022-2028.

Hemophilia A captured a dominant revenue share of 82% in the global hemophilia treatment market in 2021 due to the rising occurrence of hypertension in patients diagnosed with hemophilia A.

Recombinant factor concentrates may witness a CAGR of 5% in the global hemophilia treatment market through 2028 as they have several advantages, including high quality safety profile and reduced risk of formation of alloantibodies against recombinant factor VIII in treated patients with hemophilia A.

The non-factor replacement therapy accounted for over $1.6 billion in the overall industry in 2021 and is anticipated to observe more than 21.3% CAGR through 2028 due to its benefits, such as increasing the ability to deliver prophylaxis to patients and reducing the burden of hemophilia treatment.